Bringing Our New Drug to Patients With
Acute Myeloid Leukemia

We’re Developing

1) A best-in-class drug for a highly lethal type of blood cancer

2) A companion diagnostic to determine which patients will respond well to this drug. The diagnostic tests if a patient’s cancer is sensitive or resistant to our drug by focusing on RNA of the cancer rather than DNA. We’re currently preparing for Phase 1b/2 of clinical trials. If successful, we could improve survival and quality of life for tens of thousands of patients with cancer.

AML is a highly lethal cancer that starts in the bone marrow and causes patients to become very ill.